SV Health Investors, formerly SV Life Sciences, is a leading healthcare and life sciences venture capital and growth equity firm. Their goal is to transform healthcare – one investment at a time – by supporting the entrepreneurs who create and build breakthrough companies and treatments. With over $2 billion in capital under management in seven private healthcare funds, a 20-year track record in the US and Europe and offices in Boston, San Francisco and London, SV Health Investors drives game-changing innovation.
Nimbus Therapeutics is a biotechnology company based in Cambridge, Massachusetts, that specializes in discovering and developing innovative small molecule therapeutics for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company employs a computational technology-driven approach to advance its diverse pipeline of drug candidates into clinical development. Its Nimbus Apollo program includes the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase, which is being investigated for treating non-alcoholic steatohepatitis and hepatocellular carcinoma, among other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, and the company aims to leverage its strategic partnerships to enhance its research and development efforts. Founded in 2009, Nimbus Therapeutics continues to focus on creating highly selective and potent medicines that address unmet medical needs.
Ria Health is an online platform that offers telehealth services for individuals seeking to change their relationship with alcohol, providing personalized treatment plans, access to licensed healthcare professionals, and support through digital tools and resources for alcohol use disorder. The platform includes medication-assisted treatment options, behavioral therapies, and continuous monitoring to help users track their progress and maintain accountability. Additionally, Ria Health features a mobile app that allows users to access educational materials, connect with support groups, and communicate with care teams, ensuring a comprehensive approach to managing alcohol consumption and promoting healthier habits.
Vittoria Biotherapeutics develops gene-edited cell therapies. they provide next-generation, paradigm-shifting T-cell therapeutics that address unmet medical needs. Senza5 Technology from viTToria improves the efficacy, safety, and utility of cell-based treatments in preclinical settings.
TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.
Rondo Therapeutics is a therapeutic antibody discovery and development that creates novel bispecific antibodies that activate the immune system to fight cancer. The company was founded in 2021 and is headquartered in Hayward, California.
Eyebiotech is a vision treatment company that develops products to preserve, repair, and improve eyesight. The firm guards against sight-threatening eye disorders and developed the first anti-vascular endothelial growth factor medication for patients with age-related macular degeneration, allowing those with eye ailments to regain their eyesight.
Perfuze is a neurovascular medical device company headquartered in Galway, Ireland, focused on developing innovative catheter technology to treat acute ischemic stroke. The company aims to provide superior clinical outcomes with shorter procedural times through its catheter-based aspiration technology. The proprietary platform of the company aims to optimize the efficiency of clot removal, simplify procedures, and enhance clinical results.
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.
Alpheus Medical provides a novel sonodynamic therapy platform targeting solid body cancers. Alpheus Medical also provides a non-invasive drug-device combination for outpatient treatment of recurrent glioblastoma multiforme (rGBM).
Clarify Medical is innovating a well-established treatment, UVB therapy, to become easier, more convenient, more empowering, and more connected for psoriasis, eczema and vitiligo patients. The company also focused on developing innovative technology, products, and services that improve care for people with chronic skin conditions. Clarify Medical indicated for the localized phototherapeutic treatment of dermatologic conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis, and leukoderma on all skin types (I-VI). It is the first and only connected phototherapy system that uses an app on the patient’s own smartphone (iOS or Android) to manage the dose, frequency, and duration of UVB light therapy, helping to ensure that patients receive the proper doses recommended by the American Academy of Dermatology and Vitiligo Working Group. The treatment regimen is prescribed by the patient’s physician but monitored and controlled by the Clarify System, enabling patients to administer treatment with clinical precision in the convenience of their homes. The connected system monitors dosing, adherence, compliance, patient progress, and satisfaction.
Eyebiotech is a vision treatment company that develops products to preserve, repair, and improve eyesight. The firm guards against sight-threatening eye disorders and developed the first anti-vascular endothelial growth factor medication for patients with age-related macular degeneration, allowing those with eye ailments to regain their eyesight.
Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.
TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.
Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract.
Therini Bio is a biotechnology company specializing in fibrin-targeting therapies to treat inflammatory neurological and retinal diseases. It develops therapeutics based on unique insights into the novel role of fibrin in driving chronic innate immune activation that characterizes a broad set of human diseases with high unmet needs. The current therapeutic target is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a key driver of neuroinflammation.
Xilio Therapeutics is a biotechnology company. They offer cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. Their tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects.
PayMedix began as the healthcare payment platform for Health Payment Systems (HPS) in 2008. HPS, headquartered in Milwaukee, Wisconsin, is a privately held healthcare technology and services organization with an independent network of 96 hospital facilities and 22,600 individual providers. PayMedix has processed more than $5 billion in medical payments for hospital systems and physician practices and can be implemented with any PPO or HMO network.
Leiters is a FDA-registered 503B outsourcing provider of high quality ophthalmology and hospital-based services. We are committed to providing healthcare professionals and their patients with high quality medications. Their team of experts in sterile pharmaceutical manufacturing, repackaging, and compounding provide a sophisticated understanding of what it takes to elevate quality and consistency of supply in outsourcing. They combine their team of experts, their robust processes and their state of the art manufacturing facilities to ensure the highest quality products and services. They believe the most important consumer of their products are patients, and patients have trusted Leiters with their health for nearly a century.
Catamaran Bio is a biotechnology company that specializes in allogeneic immune cell therapies. It offers cell therapy company developing allogeneic, off-the-shelf products for patients with an unmet medical need. It was founded in 2020 and headquartered in Cambridge, Massachusetts.
Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. The company is building their transformative engine to identify drug targets and develop a pipeline of antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases. Alchemab Therapeutics was established in 2019 by Uri Laserson and Jane Osbourn in London, England.
Cellinta Limited engages in the research and development of gene therapies. It offers a platform that enables selective elimination of neural stem cells and brain cancers. Cellinta Limited was formerly known as Biotech 2 Ltd and changed its name to Cellinta Limited in February 2020. The company was founded in 2019 and is headquartered in London, United Kingdom.
Evidation measures health in everyday life and enables anyone to participate in groundbreaking research and health programs. Built upon a foundation of user privacy and control over permissioned health data, Evidation's Achievement platform is trusted by millions of individuals—generating data with unprecedented speed, scale, and rigor. We partner with leading healthcare companies to understand health and disease outside the clinic walls. Guided by our mission to enable and empower everyone to participate in better health outcomes, Evidation is working to bring people individualized, proactive, and accessible healthcare—faster. Founded in 2012, Evidation Heath is headquartered in California. We collaborate as a distributed team with additional offices around the globe. To learn more, visit evidation.com, or follow us on Twitter @evidation
Amwell is a telehealth platform in the United States and globally, connecting and enabling providers, insurers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that digital care delivery will transform healthcare. The company offers a single, comprehensive platform to support all telehealth needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With over a decade of experience, Amwell powers telehealth solutions for over 240 health systems comprised of 2,000 hospitals and 55 health plan partners with over 36,000 employers, reaching over 150 million lives. Amwell was founded in 2006 and is headquartered in Boston, Massachusetts.
Xilio Therapeutics is a biotechnology company. They offer cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. Their tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects.
Zarodex Therapeutics
Seed Round in 2020
Zarodex Therapeutics is a biotechnology company that treats dementia and Alzheimer's diseases.
Transposon Therapeutics operates as a pharmaceutical company based in Westport, Connecticut. It specializes in developing therapeutics for debilitating and life-threatening diseases
CytoMed Therapeutics is a spin-off from Singapore's Agency for Science, Technology, and Research (A*Star) that focuses on turning its patented technology into "off-the-shelf" immunotherapeutics based on gamma delta () T cells and natural killer (NK) cells treating a variety of tumors. CytoMed also generates induced pluripotent stem cells (iPSCs) and develops them into cellular medicines for its customers utilizing patented technology.
Rheostat’s mission is to invent novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy. They believe that the degradation of toxic cellular components, whether they are damaged organelles or aggregated proteins, is a fundamental node of biology. Mutations that impair these clearance pathways cause multiple neurodegenerative diseases, many of which are associated with cognitive impairment. They aim to leverage our understanding of these critical pathways to discover and develop novel small molecules that will restore cellular balance and treat neurodegenerative and rare diseases.
EBT Medical is a clinical-stage startup developing disruptive neuromodulation therapies for pelvic health disorders. EBT was founded based on scientific discoveries made at the University of Toronto and successfully incubated by their startup program, which has helped create over 500 companies in the last 10 years.
Enara Bio is a science-led company targeting the T-cell/cancer cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population. Enara Bio focuses on discovering and developing therapeutic cancer vaccines utilizing novel antigens derived from endogenous retroviral (ERV)-related DNA sequences.
Healthify builds the infrastructure to support social determinants of health initiatives at scale. The company builds and manages accountable networks of community-based organizations and provides a technology platform that streamlines the closed-loop referral process, fosters collaboration across the network, and tracks results. Healthify works with community partners, health plans, and providers in all fifty states and is dedicated to community partner sustainability and demonstrating ROI for social service interventions to ensure that families receive the services they need to thrive.
Clarify Medical is innovating a well-established treatment, UVB therapy, to become easier, more convenient, more empowering, and more connected for psoriasis, eczema and vitiligo patients. The company also focused on developing innovative technology, products, and services that improve care for people with chronic skin conditions. Clarify Medical indicated for the localized phototherapeutic treatment of dermatologic conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis, and leukoderma on all skin types (I-VI). It is the first and only connected phototherapy system that uses an app on the patient’s own smartphone (iOS or Android) to manage the dose, frequency, and duration of UVB light therapy, helping to ensure that patients receive the proper doses recommended by the American Academy of Dermatology and Vitiligo Working Group. The treatment regimen is prescribed by the patient’s physician but monitored and controlled by the Clarify System, enabling patients to administer treatment with clinical precision in the convenience of their homes. The connected system monitors dosing, adherence, compliance, patient progress, and satisfaction.
AeroCare Direct is a company based in Orlando, Florida, that specializes in distributing home medical equipment across the United States. It provides a range of products focused on respiratory therapy, including oxygen machines, CPAP/BiPAP devices, nebulizers, and associated supplies. The company caters primarily to patients suffering from chronic respiratory conditions such as Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), and Obstructive Sleep Apnea (OSA). In addition to respiratory products, AeroCare Direct also offers durable medical equipment such as wheelchairs, walkers, and canes. Notably, AeroCare Direct allows patients to purchase CPAP and respiratory supplies directly, offering an alternative to insurance-based transactions, which can often be costly or limited.
Bardy Diagnostics is a developer of a cardiac monitor and arrhythmia detection device. The company has created a new, state-of-the-art heart monitor known as Carnation Ambulatory Monitor (CAM) that can be worn comfortably and discreetly for up to 7 days. Unlike many other heart monitors, CAM can be worn during exercise or while showering. Its unique, narrow, hourglass shape makes it especially advantageous for the female anatomy. It is also designed to be comfortable for women to wear, with its narrow, hourglass shape. Bardy Diagnostics uses his expertise to develop cardiac monitoring solutions that help physicians obtain more accurate information about actionable events in the hopes of saving lives. The company's mission is to improve clinical management and outcomes for patients and their physicians by employing innovative P-wave centric ECG detection into patient-friendly technologies that result in greater patient compliance and more confident physician diagnoses. Bardy Diagnostics was founded in 2013 and is headquartered in Seattle, Washington, USA.
CSA Medical provides cryotherapy systems. It offers CryoSpray Ablation system, which enables the physicians to freeze, destroy, and remove unwanted tissues, as well as transports liquid nitrogen that is passed through a standard endoscope. CSA Medical was formerly known as Crymed Technologies and changed its name to CSA Medical in April 2006. The company was incorporated in 1993 and is based in Lutherville Timonium, Maryland.
myOrthos is a robust orthodontic platform that delivers exceptional patient care and builds a community of orthodontic excellence. They provide office management, billing and collections, capital management, and succession planning, enabling practice partners to solve many practice transition challenges.
Rheostat’s mission is to invent novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy. They believe that the degradation of toxic cellular components, whether they are damaged organelles or aggregated proteins, is a fundamental node of biology. Mutations that impair these clearance pathways cause multiple neurodegenerative diseases, many of which are associated with cognitive impairment. They aim to leverage our understanding of these critical pathways to discover and develop novel small molecules that will restore cellular balance and treat neurodegenerative and rare diseases.
Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.
Urgent Team Holdings, Inc. operates urgent care centers that provide urgent and primary health care services. It offers services for patients in the areas of sprains, strains, and broken bones; muscular pain and injuries; eye irritation and eye injuries; cuts and scrapes; bites, stings, and allergic reactions; burns and infections; diarrhea, nausea, and vomiting; flu, colds, and viral illnesses; pneumonia and bronchitis; and asthma attacks. The company also offers preventative screenings/wellness services, including flu shots, physicals, immunization and vaccinations, EKGs, and osteoporosis screening, as well as blood glucose, blood pressure, and cholesterol checks; radiology, lab work and diagnostic testing, and drug and alcohol screening services; and services for employers.
Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism. Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.
Xilio Therapeutics is a biotechnology company. They offer cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. Their tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects.
Endotronix is a developer of hemodynamic monitoring technologies to help detect worsening heart failure earlier than ever before. The company's platform includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early detection of worsening heart failure. It was founded in 2007 and is based in Lisle, Illinois.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.
Evidation measures health in everyday life and enables anyone to participate in groundbreaking research and health programs. Built upon a foundation of user privacy and control over permissioned health data, Evidation's Achievement platform is trusted by millions of individuals—generating data with unprecedented speed, scale, and rigor. We partner with leading healthcare companies to understand health and disease outside the clinic walls. Guided by our mission to enable and empower everyone to participate in better health outcomes, Evidation is working to bring people individualized, proactive, and accessible healthcare—faster. Founded in 2012, Evidation Heath is headquartered in California. We collaborate as a distributed team with additional offices around the globe. To learn more, visit evidation.com, or follow us on Twitter @evidation
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Stimwave Technologies, Inc., a medical device company, engages in the development, manufacture, commercialization, and marketing of wireless microsize injectable medical devices for neurology markets. The company was formerly known as Neural Micro Incorporated. Stimwave Technologies, Inc. was incorporated in 2010 and is based in Scottsdale, Arizona.
Centauri Health Solutions is a technology-centric company specializing in hosted software solutions, data-driven services, and data management designed specifically for risk adjustment and quality based revenue programs.
Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease. The catalyst for creating Avrobio is to accelerate scientific breakthroughs related to the convergence of cell and gene therapies. The patient’s own cells can be effectively modified to deliver novel genes to cure serious debilitating disease. Avrobio was founded by industry leaders with unmatched scientific, business, and manufacturing expertise in the field of cell and gene therapy.
Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.
Misonix has long been at the forefront of ultrasound technology and is a world leader in the design, development, manufacturing, and marketing of ultrasonic surgical devices. Their innovative, ultrasonic platforms for surgical applications include aspirators for the removal of both soft and hard tissue, instruments for laparoscopic cutting and coagulation, devices for wound cleansing and debridement, products for precision bone cutting and sculpting, liposuction instrumentation for improving body aesthetics, and High Intensity Focused Ultrasound (HIFU) systems for the ablation of tumors.
Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.
Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient’s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.
Cerevance is a biotechnology company that develops novel therapeutics for neurological diseases, including chronic neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Using a large and growing repository of over 15,000 human brain tissue samples, the company generates an unprecedented level of expression and epigenetic data, enabling the company to identify the most promising targets for the next generation of treatments for CNS disorders.
Arsanis is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to build and advance a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets. The company’s lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus. Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).
Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract.
Bardy Diagnostics is a developer of a cardiac monitor and arrhythmia detection device. The company has created a new, state-of-the-art heart monitor known as Carnation Ambulatory Monitor (CAM) that can be worn comfortably and discreetly for up to 7 days. Unlike many other heart monitors, CAM can be worn during exercise or while showering. Its unique, narrow, hourglass shape makes it especially advantageous for the female anatomy. It is also designed to be comfortable for women to wear, with its narrow, hourglass shape. Bardy Diagnostics uses his expertise to develop cardiac monitoring solutions that help physicians obtain more accurate information about actionable events in the hopes of saving lives. The company's mission is to improve clinical management and outcomes for patients and their physicians by employing innovative P-wave centric ECG detection into patient-friendly technologies that result in greater patient compliance and more confident physician diagnoses. Bardy Diagnostics was founded in 2013 and is headquartered in Seattle, Washington, USA.
Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.
Good Start Genetics is a commercial-stage molecular genetic information company focused on fundamentally transforming the standard of care in reproductive medicine by providing physicians and their patients with clinically relevant and actionable information concerning inherited genetic disorders. Good Start Genetics’ proprietary next-generation DNA sequencing (NGS) capabilities are supplemented by other proven genetic screening technologies and supported by its commitment to customer care and genetic counseling. Through GoodStart Select, the company provides a comprehensive and clinically actionable menu of genetic carrier screening tests for known and novel mutations that cause inherited genetic disorders.
NKT Therapeutics is a privately held biotechnology company focused on developing therapeutics based on unique immune cells called natural killer T (NKT) cells. The company's mission is to use its expertise to develop a pipeline of first-in-class NKT-based therapeutics to treat cancer, infectious diseases, autoimmune diseases, asthma and dermatitis.
The Company, based in Menlo Park, has developed a novel transcatheter implant called the PARACHUTETM Ventricular Partitioning Device (PARACHUTETM). The PARACHUTETM intends to treat heart failure resulting from a heart attack or myocardial infarction in millions of patients worldwide by improving overall cardiac function.
CSA Medical provides cryotherapy systems. It offers CryoSpray Ablation system, which enables the physicians to freeze, destroy, and remove unwanted tissues, as well as transports liquid nitrogen that is passed through a standard endoscope. CSA Medical was formerly known as Crymed Technologies and changed its name to CSA Medical in April 2006. The company was incorporated in 1993 and is based in Lutherville Timonium, Maryland.
SUN Behavioral Health operates hospitals that provide various behavioral health services to children, youth, adults, and seniors. The company’s services include inpatient psychiatric and substance abuse treatment, partial hospitalization programs, intensive outpatient programs, 24-hour assessments, and crisis stabilization. It also serves women, and active duty and veteran military persons. It was founded in 2013 and is headquartered in Red Bank, New Jersey.
Cibiem is a medical device company leveraging its proprietary, minimally invasive, catheter-based approach focused on Carotid Body Modulation (CBM) for the treatment of sympathetic nervous system-mediated diseases such as hypertension, heart failure, diabetes and renal failure. The company was co-founded by Mark Gelfand and Howard R. Levin, M.D., the proven team of innovators and entrepreneurs behind Coridea. The company is backed by top-tier venture investors Third Rock Ventures and SV Life Sciences.
ValenTx is a development-stage medical device company that focuses on minimally-invasive methods for the treatment of morbid obesity. The company was founded in 2002 and headquartered in Maple Grove, Minnesota.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Maestro Health is an American employee benefits company that provides integrated one-stop shopping experiences, along with private-labeled exchange solutions. It also offers employee health and benefits management solutions for brokers, small employers, and Fortune 1000 organizations. It combines private exchange, benefits administration, enrollment, self-insurance, healthcare savings account administration, and components on its integrated mobile and web platform, maestroEDGE. The company owns and operates a proprietary private exchange and medical TPA, which allows the streamlined integration of care management to drive down costs for employers.
CardioFocus is a biotechnology company that focuses on the advancement of ablation treatments for cardiac disorders. The company specializes in providing electrophysiologists with innovative and effective tools that bring new levels of precision and control to the treatment of atrial fibrillation that focuses on developing, manufacturing, and investigating disposable fiber optic catheters for the visualization of cardiac anatomy and the treatment of cardiac arrhythmias. CardioFocus was founded in 1990 and is headquartered in Marlborough, Massachusetts.
Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.
Acufocus, Inc., a medical device company, engages in the research, development, and marketing of solutions for the treatment of presbyopia. The company develops KAMRA, a corner inlay for the treatment of near vision loss that allows patients to see near and intermediate objects clearly; and AcuTarget, a system that is used to guide surgeons on surgical placement of the KAMRA.
Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.
Kesios Therapeutics Limited develops small molecule drugs for haematological malignancies, such as multiple myeloma and related indications. The company was incorporated in 2012 and is based in London, United Kingdom.
Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease. The catalyst for creating Avrobio is to accelerate scientific breakthroughs related to the convergence of cell and gene therapies. The patient’s own cells can be effectively modified to deliver novel genes to cure serious debilitating disease. Avrobio was founded by industry leaders with unmatched scientific, business, and manufacturing expertise in the field of cell and gene therapy.
Aligned Telehealth is a provider of a SaaS-based platform used to offer telemedicine and healthcare management services. Its platform offers full, end-to-end telemedicine services, including psychiatric specialty physician consultations to acute-care hospitals, emergency rooms, skilled nursing facilities, and correctional institutions that enable clients to deliver improved quality and efficient patient care.
SUN Behavioral Health operates hospitals that provide various behavioral health services to children, youth, adults, and seniors. The company’s services include inpatient psychiatric and substance abuse treatment, partial hospitalization programs, intensive outpatient programs, 24-hour assessments, and crisis stabilization. It also serves women, and active duty and veteran military persons. It was founded in 2013 and is headquartered in Red Bank, New Jersey.
Good Start Genetics is a commercial-stage molecular genetic information company focused on fundamentally transforming the standard of care in reproductive medicine by providing physicians and their patients with clinically relevant and actionable information concerning inherited genetic disorders. Good Start Genetics’ proprietary next-generation DNA sequencing (NGS) capabilities are supplemented by other proven genetic screening technologies and supported by its commitment to customer care and genetic counseling. Through GoodStart Select, the company provides a comprehensive and clinically actionable menu of genetic carrier screening tests for known and novel mutations that cause inherited genetic disorders.
HALSCION, INC. develops devices to improve wound healing and the resulting scar outcomes. The company offers single-use hydrogel scaffolds that are applied during surgery to the dermal-subdermal interface of wound by injection. Its products include biocompatible materials that provide a structural framework upon, which wound healing cells, such as fibroblasts migrate into the wound and organize. The company was incorporated in 2005 and is based in Suwanee, Georgia.
Direct Flow Medical is a medical device company developing a percutaneous aortic tissue valve prosthesis to provide patients requiring treatment of cardiac valve insufficiency with a safe and effective percutaneous option. Approximately 1.2 million people over the age of 65 have calcified aortic valves, yet only an estimated 150,000 are surgically treated each year.
Endotronix is a developer of hemodynamic monitoring technologies to help detect worsening heart failure earlier than ever before. The company's platform includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early detection of worsening heart failure. It was founded in 2007 and is based in Lisle, Illinois.
Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient’s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.
CardioFocus is a biotechnology company that focuses on the advancement of ablation treatments for cardiac disorders. The company specializes in providing electrophysiologists with innovative and effective tools that bring new levels of precision and control to the treatment of atrial fibrillation that focuses on developing, manufacturing, and investigating disposable fiber optic catheters for the visualization of cardiac anatomy and the treatment of cardiac arrhythmias. CardioFocus was founded in 1990 and is headquartered in Marlborough, Massachusetts.
Acufocus, Inc., a medical device company, engages in the research, development, and marketing of solutions for the treatment of presbyopia. The company develops KAMRA, a corner inlay for the treatment of near vision loss that allows patients to see near and intermediate objects clearly; and AcuTarget, a system that is used to guide surgeons on surgical placement of the KAMRA.
Karus is an emerging pharmaceutical company whose R&D activities are focused on the design and development of innovative, molecular-targeted, small molecule drugs to treat immune/inflammatory disorders and cancer.
Arsanis is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to build and advance a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets. The company’s lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus. Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).
JET Health Solutions is a healthcare technology company focused on providing smart solutions for healthcare payers across the country. Our flagship product, JET Insure, is a quote-to-card (Q2C) insurance automation platform that provides individual/family plans, group plans, stop-loss/self-funded options, and specialty products on a single, cloud-based solution.
TopiVert is a clinical-stage biotechnology company developing next-generation, Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, non-systemic medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and the eye. The lead GI programme TOP1288 is currently in a Phase IIa proof of concept study in ulcerative colitis. A Phase I/II study with TOP1630 for dry eye syndrome will commence in the US in early 2017.
VHsquared is dedicated to the development of novel antibody domains engineered to be stable in the GI tract. Their novel antibody platform will provide a portfolio of new and innovative functional food products to target gastrointestinal infectious and immune mediated diseases. There has been an explosion of interest in foods that have additional physiological benefits. VHsquared leverages the existing research and expertise at the Sanger Institute to facilitate the development of products that function at the GI mucosal interface harnessing recent technological developments, including analysis of the microbiota and advances in mucosal immunology. Conventional antibodies are degraded in the gut and therefore efficacy obtained from oral administration is limited. VHsquared uses domain antibodies that can be selected and engineered to resist degradation, are intrinsically very stable and are locally active in the gastrointestinal tract. Products will offer advantages in terms of specificity, safety, efficacy, convenience and cost.
Arsanis is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to build and advance a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets. The company’s lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus. Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).
Good Start Genetics is a commercial-stage molecular genetic information company focused on fundamentally transforming the standard of care in reproductive medicine by providing physicians and their patients with clinically relevant and actionable information concerning inherited genetic disorders. Good Start Genetics’ proprietary next-generation DNA sequencing (NGS) capabilities are supplemented by other proven genetic screening technologies and supported by its commitment to customer care and genetic counseling. Through GoodStart Select, the company provides a comprehensive and clinically actionable menu of genetic carrier screening tests for known and novel mutations that cause inherited genetic disorders.
AeroCare Direct is a company based in Orlando, Florida, that specializes in distributing home medical equipment across the United States. It provides a range of products focused on respiratory therapy, including oxygen machines, CPAP/BiPAP devices, nebulizers, and associated supplies. The company caters primarily to patients suffering from chronic respiratory conditions such as Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), and Obstructive Sleep Apnea (OSA). In addition to respiratory products, AeroCare Direct also offers durable medical equipment such as wheelchairs, walkers, and canes. Notably, AeroCare Direct allows patients to purchase CPAP and respiratory supplies directly, offering an alternative to insurance-based transactions, which can often be costly or limited.
Acufocus, Inc., a medical device company, engages in the research, development, and marketing of solutions for the treatment of presbyopia. The company develops KAMRA, a corner inlay for the treatment of near vision loss that allows patients to see near and intermediate objects clearly; and AcuTarget, a system that is used to guide surgeons on surgical placement of the KAMRA.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Cibiem is a medical device company leveraging its proprietary, minimally invasive, catheter-based approach focused on Carotid Body Modulation (CBM) for the treatment of sympathetic nervous system-mediated diseases such as hypertension, heart failure, diabetes and renal failure. The company was co-founded by Mark Gelfand and Howard R. Levin, M.D., the proven team of innovators and entrepreneurs behind Coridea. The company is backed by top-tier venture investors Third Rock Ventures and SV Life Sciences.
Maestro Health is an American employee benefits company that provides integrated one-stop shopping experiences, along with private-labeled exchange solutions. It also offers employee health and benefits management solutions for brokers, small employers, and Fortune 1000 organizations. It combines private exchange, benefits administration, enrollment, self-insurance, healthcare savings account administration, and components on its integrated mobile and web platform, maestroEDGE. The company owns and operates a proprietary private exchange and medical TPA, which allows the streamlined integration of care management to drive down costs for employers.
Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.
Acufocus, Inc., a medical device company, engages in the research, development, and marketing of solutions for the treatment of presbyopia. The company develops KAMRA, a corner inlay for the treatment of near vision loss that allows patients to see near and intermediate objects clearly; and AcuTarget, a system that is used to guide surgeons on surgical placement of the KAMRA.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.